^
    No biomarker
    Esophageal Adenocarcinoma
    nivolumab
    Sensitive
    :
    A1
    FDA - 3wk
    No biomarker
    Esophageal Adenocarcinoma
    ramucirumab
    Sensitive
    :
    A2
    HER-2 positive
    Esophageal Adenocarcinoma
    trastuzumab
    Sensitive
    :
    A2
    HER-2 overexpression
    Esophageal Adenocarcinoma
    trastuzumab
    Sensitive
    :
    A2
    PD-L1 expression
    Esophageal Adenocarcinoma
    pembrolizumab
    Sensitive
    :
    A2
    No biomarker
    Esophageal Adenocarcinoma
    FP
    Sensitive
    :
    A2
    No biomarker
    Esophageal Adenocarcinoma
    FLOT
    Sensitive
    :
    A2
    HER-2 Negative + PD-L1 expression
    Esophageal Adenocarcinoma
    nivolumab
    Sensitive
    :
    A2
    No biomarker
    Esophageal Adenocarcinoma
    FOLFOX
    Sensitive
    :
    A2
    HER-2 overexpression
    Esophageal Adenocarcinoma
    fam-trastuzumab deruxtecan-nxki
    Sensitive
    :
    A2
    PD-L1 expression
    Esophageal Adenocarcinoma
    nivolumab
    Sensitive
    :
    B
    HER-2 positive
    Esophageal Adenocarcinoma
    trastuzumab + pertuzumab
    Sensitive
    :
    C1
    CLDN18.2 expression
    Esophageal Adenocarcinoma
    IMAB362
    Sensitive
    :
    C2
    HER-2 amplification
    Esophageal Adenocarcinoma
    trastuzumab + avelumab
    Sensitive
    :
    C2
    HER-2 positive
    Esophageal Adenocarcinoma
    paclitaxel
    Resistant
    :
    C3
    HER-2 positive
    Esophageal Adenocarcinoma
    carboplatin
    Resistant
    :
    C3
    DKK1 overexpression
    Esophageal Adenocarcinoma
    pembrolizumab + DKN-01
    Sensitive
    :
    C3
    DKK1 overexpression
    Esophageal Adenocarcinoma
    DKN-01
    Sensitive
    :
    C3
    GRB7 positive
    Esophageal Adenocarcinoma
    trastuzumab + carboplatin + paclitaxel + pertuzumab
    Sensitive
    :
    C3
    HER-2 overexpression
    Esophageal Adenocarcinoma
    trastuzumab + pertuzumab
    Sensitive
    :
    C3
    ERCC1 negative
    Esophageal Adenocarcinoma
    SOX
    Sensitive
    :
    C3
    MSI-H/dMMR + MLH1 deletion + PMS2 deletion
    Esophageal Adenocarcinoma
    pembrolizumab
    Sensitive
    :
    C4
    VERI is free for non-commercial use, no login needed.
    Content on this site is for research purposes only and is not intended  to be a substitute for medical advice.
    For commercial access, including additional premium features, please contact us.
    By using VERI, you are agreeing to our
    and
    Privacy Policy
    ACCEPT COOKIES